The judges also explored the practical fallout
You can think of it as sending the body a coordinated set of signals that reduce hunger, improve how we handle food, and gently nudge us to burn more energy
Retatrutide (LY3437943) is a synthetic peptide investigated in preclinical and phase 2 research models as a triple agonist of GLP-1, GIP, and glucagon receptors
It is a master producer of butyratea short-chain fatty acid that triggers your body to release its own fullness hormones, GLP-1 and PYY
Exclusivity: What You Need to Know Its important to understand the distinction between patent protection and market exclusivity: Patent protection lasts 20 years from the date of filing and can protect against any competitor trying to copy the drugs formulation or manufacturing process
Sudden discontinuation can lead to rapid weight regain and potential metabolic disturbances, which can undermine the progress made during treatment